Pharmacogenetic testing revisited: 5′nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
Jens Borggaard Larsen, Jan Borg Rasmussen Laboratory Unit, Danish Epilepsy Centre, Filadelfia, Dianalund, Denmark Abstract: Due to their involvement in the metabolization of commonly prescribed psychopharmaceutical drugs, the cytochrome oxidase genes CYP2D6 and CYP2C19 are extensive targets...
Saved in:
Main Authors: | Larsen JB (Author), Rasmussen JB (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2017-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015) -
THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015) -
The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
by: Ping Siu Kee, et al.
Published: (2023) -
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
by: Kelly E. Caudle, et al.
Published: (2020) -
Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
by: Alison E. Fohner, et al.
Published: (2020)